Leigh Syndrome: Clinical Trials

6 trials for Leigh Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 enrolling by invitation, 1 not yet recruiting, 1 terminated. 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 2, Enrolling by invitation 1, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 31Terminated 1

Follow Leigh Syndrome: new trials by email Literature Review of Leigh Syndrome trials Research Report on Leigh Syndrome

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)
TTI-0102: cysteamine-pantetheine disulfide, D-Mannitol - Leigh Syndrome
Phase 2Not yet recruitingThiogenesis Therapeutics, Inc.182026-10-012026-07-24
Sirolimus for Leigh Syndrome
Sirolimus - Leigh Syndrome
Phase 2Enrolling by invitationMatthew Demczko152025-02-272026-03-31
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
ABI-009 - Leigh Syndrome
Phase 2WithdrawnAadi Bioscience, Inc.2022-04-302022-02-01
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy
Phase 2 / Phase 3TerminatedPTC Therapeutics682020-09-282026-03-31
Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome
EPI-743 - Leigh Syndrome
Phase 2CompletedPTC Therapeutics302014-01-312024-10-23
Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
Placebo, EPI-743 15 mg/kg, EPI-743 5 mg/kg - Leigh Syndrome
Phase 2CompletedPTC Therapeutics352012-10-312020-08-31

Narrower conditions

Leigh Disease (6)  ·  Mitochondrial Diseases (3)  ·  Diffuse Cerebral Sclerosis of Schilder (1)  ·  Drug Resistant Epilepsy (1)  ·  MELAS Syndrome (1)  ·  MERRF Syndrome (1)  ·  Mitochondrial encephalopathy (1)  ·  Nerve Degeneration (1)  ·  Pontocerebellar Hypoplasia Type 6 (1)  ·  Seizures (1)  ·  Status Epilepticus (1)

Broader conditions

Brain Diseases (6)  ·  Brain Diseases, Metabolic (6)  ·  Brain Diseases, Metabolic, Inborn (6)  ·  Carbohydrate Metabolism, Inborn Errors (6)  ·  Central Nervous System Diseases (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (6)  ·  Metabolic Diseases (6)  ·  Metabolism, Inborn Errors (6)  ·  Nervous System Diseases (6)  ·  Nutritional and Metabolic Diseases (6)  ·  Pyruvate Metabolism, Inborn Errors (6)  ·  Mitochondrial Diseases (3)  ·  Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)

Interventions

alpha-tocotrienol quinone (3)  ·  Mannitol (1)  ·  Sirolimus (1)  ·  cysteamine-pantetheine disulfide (1)

Sponsors

PTC Therapeutics (3)  ·  Aadi Bioscience, Inc. (1)  ·  Matthew Demczko (1)  ·  Thiogenesis Therapeutics, Inc. (1)

Countries

United States (4)  ·  Canada (1)  ·  France (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Bruce Cohen, MD (1)  ·  Matthew Demczko, MD (1)  ·  Patrice Rioux, MD, PhD (1)  ·  Vinay Penematsa, MD (1)  ·  Zarazuela Zolkipli-Cunningham, MBChB, MRCP (1)